IDEXX Laboratories (NASDAQ:IDXX) Issues FY 2026 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 14.690-14.940 for the period, compared to the consensus earnings per share estimate of 14.640. The company issued revenue guidance of $4.7 billion-$4.7 billion, compared to the consensus revenue estimate of $4.7 billion.

IDEXX Laboratories Stock Performance

IDXX stock traded down $1.28 during mid-day trading on Thursday, reaching $583.50. The company had a trading volume of 193,396 shares, compared to its average volume of 585,681. IDEXX Laboratories has a one year low of $518.55 and a one year high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $46.03 billion, a P/E ratio of 41.03, a P/E/G ratio of 3.21 and a beta of 1.54. The stock’s 50-day simple moving average is $558.83 and its two-hundred day simple moving average is $586.67.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the prior year, the business posted $3.50 earnings per share. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Research analysts anticipate that IDEXX Laboratories will post 14.74 EPS for the current year.

Analysts Set New Price Targets

IDXX has been the subject of a number of research analyst reports. Citigroup upped their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. UBS Group lifted their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $756.00.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Advisory Services Network LLC lifted its stake in IDEXX Laboratories by 2.5% in the 4th quarter. Advisory Services Network LLC now owns 752 shares of the company’s stock valued at $509,000 after buying an additional 18 shares in the last quarter. Quadrant Capital Group LLC raised its holdings in shares of IDEXX Laboratories by 1.0% during the 4th quarter. Quadrant Capital Group LLC now owns 2,046 shares of the company’s stock worth $1,384,000 after acquiring an additional 20 shares during the period. Kelleher Financial Advisors lifted its position in IDEXX Laboratories by 3.1% in the third quarter. Kelleher Financial Advisors now owns 832 shares of the company’s stock valued at $532,000 after buying an additional 25 shares during the last quarter. L2 Asset Management LLC lifted its stake in IDEXX Laboratories by 6.7% during the fourth quarter. L2 Asset Management LLC now owns 399 shares of the company’s stock worth $270,000 after purchasing an additional 25 shares in the last quarter. Finally, Illinois Municipal Retirement Fund boosted its stake in shares of IDEXX Laboratories by 0.4% in the fourth quarter. Illinois Municipal Retirement Fund now owns 6,496 shares of the company’s stock valued at $4,395,000 after purchasing an additional 26 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.